Blue Matter

Medical Affairs Success Factor 5 - Insights-Strategy-Action Loop Don't bury insights in slide decks... When properly harnessed, #MedicalAffairs insights refine strategy, direct resources, & drive enterprise value. But how can MA empower team members to generate actionable insights & make sure they get applied to the real world? Learn more in our latest report by Chirag Ghai & Thomas Quirk >> https://lnkd.in/e3JQ8f5E

Medical Affairs Success Factor 4 - Capabilities & Systems Increasingly, #MedicalAffairs needs a fit-for-purpose, scalable “system” in place to create insights, generate evidence, tell the scientific story, & more. But why? And what are the essential elements? Find out in our latest report by Chirag Ghai & Thomas Quirk >> https://lnkd.in/e3JQ8f5E

The annual meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research concluded in Montreal late last week. Here, Chirag Ghai, Tom Bernstein, & Cameron Wong provide a concise look at the key topics discussed at the conference >> https://lnkd.in/eyGgua-w

Confused about the possibility of #MostFavoredNation pricing for prescription pharmaceuticals? Here, we explore what's known & unknown, how President Trump's #ExecutiveOrder fits into the larger picture, & some strategic questions #biopharma leaders might need to ask themselves. (Part 1 in a series, by Kurt Hartman, Naina Shehzeen A., & Steve Schollmeyer) >> https://lnkd.in/eBgmQEy8 #biotech #pharmaceuticals #drugprices

Much has been written over the past few days about the Trump administration's executive order of May 12 regarding #MostFavoredNation pricing for prescription pharmaceuticals. In this article, we take a look at what's known, what's unknown, how this EO fits into the larger picture, & some strategic questions #biopharma leaders might need to ask themselves. This is part 1 in an upcoming series >> https://lnkd.in/eBgmQEy8 Authors: Kurt Hartman, Naina Shehzeen A., & Steve Schollmeyer #biotech #pharmaceuticals #executiveorder #MFN #drugpricing

Yesterday, Blue Matter brought together 20+ influential biotech leaders for a roundtable discussion on the rapidly evolving UK #biotech landscape.   The UK has always supported a vibrant spin-out ecosystem that plays a critical role in advancing early-stage innovation. Significant challenges remain in translating these breakthroughs into accessible, life-saving therapies for patients.   The discussion focused on some of the sector’s top priorities; from making decisions around new product portfolio strategy, to securing the right investment, partnerships, and talent needed to sustain impactful discovery and clinical development pipelines.   All of this is unfolding against a backdrop of economic volatility and uncertainty around the potential short- and long-term effects of US policy changes, with the potential to drive increased risk aversion among investors and big pharma. The conversation led towards opportunity identification within an environment where product differentiation and value demonstration is becoming all the more critical.   A huge thank you to everyone who brought their insight and commitment to the conversation which remains far from over. In the coming weeks, we will be sharing a more detailed analysis exploring the key implications and opportunities that lie ahead for the sector. #biopharma #pharmaceuticals #UKBiotech

The annual meeting of American Society of Clinical Oncology (ASCO) is coming up in Chicago, May 30 - June 3. Be sure to connect with our team there: Mary Lee, Chirag Ghai, Naina Shehzeen A., Shankar Sundar, & Lily Sung. #ASCO25 #cancerresearch #oncology #biotech #pharmaceuticals

Medical Affairs Success Factor 3 - Creativity & Integrative Thinking For #MedicalAffairs, Science + Strategy = Superpower.  Being brilliant at science isn’t enough anymore. MA’s true magic happens when it blends scientific credibility with business acumen to drive impact.  Learn how in our latest report by Chirag Ghai & Thomas Quirk >> https://lnkd.in/e3JQ8f5E #biotech #pharmaceuticals #BPO #BestPracticeOrganization

NEW >> Continuing with our series on #DecisionScience, this article outlines a framework for making better decisions within the context of #biopharma portfolio strategy development (though it can be applied to any decision-making process). Authors: Deepak Veeraraghavan, Dr. Florian Methling, Rüdiger von Nitzsch https://lnkd.in/ezQ6trbi #portfoliostrategy #biotech #pharmaceuticals

The American Society of Clinical Oncology (ASCO) has its annual meeting coming up in Chicago, May 30-June 3. Members of the Blue Matter team will be attending sessions & meeting with clients & colleagues. Connect with the team there! >> Mary Lee, Naina Shehzeen A., Shankar Sundar, & Lily Sung. #oncology #ASCO25 #biotech #pharmaceutical #cancerresearch